Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.

Galadanci NA, Abdullahi SU, Ali Abubakar S, Wudil Jibir B, Aminu H, Tijjani A, Abba MS, Tabari MA, Galadanci A, Borodo A, Belonwu R, Salihu AS, Rodeghier M, Ghafuri DL, Covert C Greene BV, Neville K, Kassim AA, Kirkham FJ, Jordan LC, Aliyu MH, DeBaun MR. Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial. American journal of hematology. 2020 Jun 8. PMID: 32510680 [PubMed]